or Try an Advanced Search...

    Technical Analysis for AKBA - Akebia Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.99 -2.51% -0.03
    AKBA closed down 2.51 percent on Monday, July 1, 2024, on 1.3 times normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical AKBA trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    20 DMA Resistance Bearish -2.51%
    MACD Bullish Signal Line Cross Bullish -2.51%
    Pocket Pivot Bullish Swing Setup -2.51%
    Volume Surge Other -2.51%
    Wide Bands Range Expansion -2.51%
    Up 3 Days in a Row Strength -2.51%
    Pocket Pivot Bullish Swing Setup 0.53%
    Lower Bollinger Band Walk Weakness 0.53%
    Older End-of-Day Signals for AKBA ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 8 hours ago
    60 Minute Opening Range Breakdown about 8 hours ago
    Down 2 % about 8 hours ago
    Rose Above Previous Day's High about 9 hours ago
    Up 2% about 9 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AKBA Chart by TradingView
    Basic chart:

    Profile

    Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Biology Kidney Disease Dialysis Anemia Chronic Kidney Disease Kidney Hypoxia Inducible Factors

    Is AKBA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
    Jun 24 Akebia Therapeutics names Erik Ostrowski as CFO
    Jun 24 Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer
    Jun 21 Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%
    May 23 Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
    May 14 Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
    May 11 Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
    May 10 Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
    May 10 Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
    May 10 Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations
    See more AKBA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.48
    52 Week Low 0.7801
    Average Volume 3,332,447
    200-Day Moving Average 1.27
    50-Day Moving Average 1.16
    20-Day Moving Average 1.03
    10-Day Moving Average 0.96
    Average True Range 0.08
    RSI (14) 43.82
    ADX 28.92
    +DI 16.32
    -DI 25.15
    Chandelier Exit (Long, 3 ATRs) 0.94
    Chandelier Exit (Short, 3 ATRs) 1.05
    Upper Bollinger Bands 1.21
    Lower Bollinger Band 0.86
    Percent B (%b) 0.39
    BandWidth 33.49
    MACD Line -0.06
    MACD Signal Line -0.07
    MACD Histogram 0.0069
    Fundamentals Value
    Market Cap 187.33 Million
    Num Shares 188 Million
    EPS -0.31
    Price-to-Earnings (P/E) Ratio -3.21
    Price-to-Sales 1.61
    Price-to-Book 4.12
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.11
    Resistance 3 (R3) 1.12 1.08 1.09
    Resistance 2 (R2) 1.08 1.05 1.08 1.09
    Resistance 1 (R1) 1.04 1.04 1.02 1.03 1.08
    Pivot Point 1.01 1.01 1.00 1.00 1.01
    Support 1 (S1) 0.96 0.97 0.94 0.95 0.91
    Support 2 (S2) 0.93 0.96 0.92 0.90
    Support 3 (S3) 0.88 0.93 0.90
    Support 4 (S4) 0.88